AstraZeneca Divests Antidiabetics To 3SBio In New China Growth Plan
Executive Summary
AstraZeneca has out-licensed Chinese commercial rights to four antidiabetics to Shenyang’s 3SBio, reflecting the UK firm's increasing focus on its core respiratory franchise and new products, while 3SBio is looking to expand into new areas.